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OCULAR CORMOBIDITIES IN NEONATAL ABSTINENCE SYNDROME 
HAN NA PARK 
ABSTRACT 
Chronic opioid exposure in utero places the infant at risk of Neonatal Abstinence 
Syndrome (NAS), a clinical diagnosis of neurological, autonomic, and/or gastrointestinal 
withdrawal symptoms from opioid abstinence at birth. The prevalence of NAS is rising 
concurrently with the recent epidemic of opioid misuse among the general population in 
the United States, including pregnant women. Opioid misusing women typically receive 
methadone or buprenorphine as a treatment throughout pregnancy. However, the opioid 
misuse during pregnancy is associated with higher obstetric complications and a higher 
incidence of NAS in infants, at times requiring pharmacological intervention. The exact 
consequences to the human development from opioid exposure in utero remain unclear.  
 Animal studies suggest that the fetal impacts of opioid exposure may differ from 
the consequences for an adult who uses opioids. Furthermore, there may be 
neurodevelopmental alterations in myelin physiology, dendritic length in the brain, and 
neurotransmitter systems when a child is exposed to opioids in utero. Clinical studies 
highlight associations between perinatal opioid exposure and gene mutation variants, 
cranial abnormalities on imaging, and a high prevalence of ocular and visual 
comorbidities. Ocular and visual comorbidities are of particular interest, because they 
may be treatable when detected early. 
 The current literature about NAS infants and ocular and visual comorbidities is 
limited by the retrospective and small case-control study designs employed by the 
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majority of the research groups. The proposed study design is a prospective study 
comparing groups of opioid exposed and non-opioid exposed infants born at Boston 
Medical Center in Boston, Massachusetts. The ocular and visual comorbidities detected 
in each group will be quantified, while analyzing the relationship and the relative risk 
attributable to the infant’s and mother’s demographics. The social context of opioid 
misuse may complicate the interpretation of the data; however, the design anticipates 
sufficient recruitment and generalizability as it is conducted at a safety net hospital. 
Ultimately, the goal of this proposal is to reduce the risk to the fetus with perinatal opioid 
exposure and build the knowledge base about ocular comorbidities in NAS infants so that 
optimal and comprehensive care can be provided in the future.  
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TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
ACKNOWLEDGMENTS ................................................................................................. iv 
ABSTRACT ........................................................................................................................ v 
TABLE OF CONTENTS .................................................................................................. vii 
LIST OF TABLES ............................................................................................................. ix 
LIST OF FIGURES ............................................................................................................ x 
LIST OF ABBREVIATIONS ............................................................................................ xi 
INTRODUCTION .............................................................................................................. 1 
Background ..................................................................................................................... 1 
Statement of the Problem ................................................................................................ 2 
Hypothesis....................................................................................................................... 2 
Objectives and specific aims ........................................................................................... 3 
REVIEW OF THE LITERATURE .................................................................................... 4 
Overview ......................................................................................................................... 4 
Synthesis of Existing Research ..................................................................................... 16 
METHODS ....................................................................................................................... 23 
  viii 
Study design .................................................................................................................. 23 
Study population and sampling ..................................................................................... 23 
Study variables and measures ....................................................................................... 24 
Recruitment ................................................................................................................... 24 
Data collection .............................................................................................................. 26 
Data analysis by specific aims ...................................................................................... 27 
Timeline and resources ................................................................................................. 28 
Institutional Review Board ........................................................................................... 29 
DISCUSSION ................................................................................................................... 30 
Discussion ..................................................................................................................... 30 
Summary ....................................................................................................................... 31 
Clinical and public health significance ......................................................................... 32 
LIST OF JOURNAL ABBREVIATIONS........................................................................ 33 
REFERENCES ................................................................................................................. 38 
CURRICULUM VITAE ................................................................................................... 50 
 
  
  ix 
LIST OF TABLES 
 
 
Table Title Page 
1 Percentage of infants evaluated by 
ophthalmologist/orthoptist   
19 
2 Prevalence of ocular comorbidities in studies with 
perinatal drug exposure/NAS infants compared to the 
general population 
20 
3 Demographic information to be collected from the mother 
and infant 
25 
 
 
 
  
  x 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Neonatal Abstinence Scoring System 12 
 
 
 
 
 
 
  
  xi 
LIST OF ABBREVIATIONS 
 
 
AAP ................................................................................  American Academy of Pediatrics 
B.C. ............................................................. Before Christ (Julian and Gregorian calendars) 
BMC  ................................................................................................ Boston Medical Center 
COMT ..................................................................................... catechol-o-methyltransferase 
DC  ...............................................................................................  The District of Columbia 
DCF  .......................................................................... Department of Children and Families 
DOPAC  ............................................................................ 3-4 Dihydroxyphenylacetic Acid 
EMR  ......................................................................................... Electronic Medical Records 
IRB ............................................................................................  Institutional Review Board 
MBP  ....................................................................................................Myelin Basic Protein 
MOPEG......................................................................... 3-Methoxy-4-hydroxyphenylglycol 
NAS..................................................................................... Neonatal Abstinence Syndrome 
NICU ....................................................................................... Neonatal Intensive Care Unit 
NSDUH ................................................................National Survey on Drug Use and Health 
OPRM1 ............................................................................................ Opioid Receptor, Mu 1 
PNOC ......................................................................................................... Prepronociceptin 
 
 
 
 1 
INTRODUCTION 
Background 
The rapid increase of drug misuse in the United States has brought much attention to its 
widespread ramifications and social burden. According to the 2014 National Survey on 
Drug Use and Health (NSDUH), one in ten people aged 12 and above, have misused 
prescription drugs in the past month1. Prescription drugs in the pharmacological classes 
of analgesics, stimulants, and anxiolytics are among the most widely misused. Each drug 
has its own unique chemical profile, side effects, and addictive properties. When drug 
dependence develops, an individual often suffers physiological, financial, and social 
consequences requiring professional attention and treatment. 
 Women of child-bearing age (15-44 years old) are no exception and have also 
reported misuse of prescription drugs during pregnancy. Medicaid data collected between 
2000 and 2007 suggests that almost 2% of pregnant women had a prior history of opioid 
abuse and/or dependence2. The misuse of opioid analgesics may be attributed to their use 
for treatment of chronic pain, especially since a risk has been identified in animal fetus, 
but no confirmatory human studies are currently available (Category C drugs defined by 
United States Food and Drug Administration). 
Infants exposed to drugs of misuse chronically in utero are at risk of developing 
Neonatal Abstinence Syndrome (NAS)3–5, a constellation of neurological, 
gastrointestinal, and autonomic withdrawal symptoms that require a combination of non-
pharmacologic and/or pharmacologic treatment. The first case of neonatal withdrawal 
was reported in 18755 and more recently, an epidemic of neonatal withdrawal symptoms 
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have occurred in the United States. By 2013, 213 neonatal intensive care units (NICUs) 
across the United States had greater than 100 admissions of NAS infants per year6. NAS 
is prevalent among infants exposed to opiates in utero, with an incidence that ranges from 
55 to 94%7. This manuscript will focus only on opioid misuse unless stated otherwise, 
although, NAS symptomology has been reported in neonates exposed to concomitant 
misuse of tobacco and/or prescription-type psychotherapeutics with opioids8,9.  
 
Statement of the Problem 
Both animal and clinical studies show a close relationship between perinatal opiate 
exposure and neurodevelopmental abnormalities10–14. Ocular comorbidities may be a 
potential confounder in accurately understanding the development of NAS infants.  
Recent publications, mostly retrospective cohort or small case-control studies, have 
characterized several ocular comorbidities among NAS children15–19. For example, in a 
retrospective study conducted in 2014 at Boston Medical Center (BMC), strabismus 
(49.3%), refractive error (20.9%), and nystagmus (17.9%) were more commonly seen in 
the NAS cohort than in the general population18. 
 
Hypothesis 
NAS infants exhibit a significantly greater prevalence of ocular comorbidities, namely, 
strabismus, refractive error, nystagmus, and optic nerve abnormalities than non-drug-
exposed infants. 
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Objectives and specific aims 
The broad objective of this proposal is to understand the ocular and visual comorbidities 
in NAS infants using a prospective cohort design with demographically matched control 
subjects. This will allow a comparison of prevalence of ocular and visual comorbidities in 
drug-exposed vs. non-drug-exposed infants, controlling for gestational age, birthweight, 
and socioeconomic status, while characterizing ocular comorbidities at our institution 
(Boston Medical Center). A prospective design will provide stronger epidemiologic 
evidence to monitor data collection and calculate absolute risk for the population studied 
in the same passage of time and space between different study groups, while minimizing 
the biases seen in previous case-control studies and retrospective studies20. The study 
design will achieve the following specific aims: 
 Compare the prevalence of ocular and visual comorbidities between NAS infants 
and non-drug-exposed infants 
 Assess the relationship between length of exposure and dose of opioids and 
intrauterine concomitant substances exposure to the prevalence of ocular and 
visual comorbidities 
 Assess the impact of patient demographics on ocular and visual comorbidities in 
NAS infants  
 4 
REVIEW OF THE LITERATURE 
Overview 
History of opiate use and misuse 
Opium, a natural extract derived from the poppy plant Papaver somniferum, is 
one of the oldest recorded medical prescriptions drugs, dating back as early as 2100 
B.C21.  Some of the earliest indications for opium use were diarrhea, diseases of the eye, 
and post-limb amputation analgesia 21. The term opioid was first used by Acheson to 
refer to compounds with morphine-like properties despite the difference in chemical 
structure.  Formulations of morphine and heroin were isolated from opium in the early 
1800’s21, heralding a major advance in pharmaceutical science and increasing opioid 
availability to the public.   
Opioid agents are currently used to produce temporary analgesia by their action as 
mu (μ)-opioid receptor agonists. Sold under various labels including hydrocodone, 
oxycodone, fentanyl, and morphine, opioid prescription rates have increased 
dramatically22, especially as several small population studies in the 1980s and 1990s 
suggested opioids for chronic non-malignant pain23. In 2011, hydrocodone surpassed all 
other medications, ranking as the number one dispensed prescription medication in the 
United States with 136.7 million prescriptions22.    
With the increase of opioid prescriptions, opioid misuse has also increased. As 
highlighted above, a large population study of Medicaid data from 2000 to 2007, 
extracted from 46 states and Washington DC, reported 34,111 (11.9%) pregnant women 
taking prescription opioids for greater than 30 days (median of 55 days) and 4,816 (1.7%) 
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pregnant women having a documented history of opioid misuse/dependence2. The direct 
causal relationship between the increase of opioid prescriptions and the increase of opioid 
misuse would be difficult to determine empirically due to clinical study design 
limitations23 and the ethical concerns of promoting misuse. However, it is worth 
mentioning the wide accessibility of prescription opioid medication to pregnant women 
and potential misuse which may occur, when as many as 88.3% of pregnant women from 
Medicaid data filled opioid prescriptions for less than a 30 day supply at least once in an 
outpatient setting2. 
A 2003 study in The Lancet named heroin, an opioid, the most dangerous drug 
based on the categories of “its physical harm to the user,” “addictive potential,” and 
“overall negative impact on society.”7,24 Abuse, first described in women as early as the 
19th century25, arises when repetitive and prolonged use results in both physical and 
psychological dependence26. Abrupt opioid withdrawal in a dependent individual will 
present an array of signs and symptoms including nausea, vomiting, restlessness, 
piloerection, mydriasis, rhinorrhea, and hyperthermia27.  
Methadone and buprenorphine are the treatments for opioid misuse and 
dependence due to their long-acting pharmacological properties. Methadone, a synthetic 
opioid agonist and N-Methyl-d-aspartate antagonist, has a half-life of approximately 12-
36 hours5,28. Buprenorphine, a semi-synthetic partial μ-receptor agonist and κ-receptor 
antagonist, has a half-life of 12 hours5,28. The advantages to long-acting formulations are 
prolonged systemic effects, less frequent dosing, delayed withdrawal, and reduced drug-
seeking behavior. In previous publications, both methadone and buprenorphine were 
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shown to be equally safe and effective therapies for opioid misusing pregnant women29–
31. 
The methadone and buprenorphine maintenance therapy is “part of a 
comprehensive package,” which the pregnant mother receives daily dispensed from a 
registered substance treatment program along with indicated prenatal care, chemical 
dependency counseling, and other psychosocial services32. With the increase in maternal 
misuse of drugs, the incidence of NAS has risen at alarming rates. In a review of 299 
neonatal intensive care units, admissions for NAS increased from 7 cases to 27 cases per 
1,000 admissions, with a median length of stay increasing from 13 to 19 days, from 2004 
to 20136. In Massachusetts, the number of NAS infants increased from 2.35 to 14.68 per 
1,000 hospital births within the same period33. At the institution of Boston Medical 
Center (BMC) alone, there were 106 and 112 reported cases of “substance exposed 
newborn” in 2013 and 2014, respectively34.  
A mother’s withdrawal has been associated with increased fetal activity, fetal 
mortality35–37, and an increase in the mother’s susceptibility to dangerous drug-seeking 
and health-risking behaviors. For instance, 75% of mothers with heroin abuse disorder do 
not seek necessary prenatal care38. Consequently, methadone and buprenorphine 
maintenance therapies are recommended as research studies show their important 
associations with improved neonatal outcomes39,40.   
 
Effects of drugs of abuse in utero 
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NSDUH data reveal that the drugs abused by pregnant women range from 
marijuana/hashish to cocaine, heroin, hallucinogens, inhalants, and prescription 
psychotherapeutics. Polysubstance abuse is also a concern since these drugs are often 
used concurrently with tobacco and/or alcohol1,7,41; drugs can affect the fetus and later the 
infant, when they cross the placenta or transmit through breast milk7.   
Fetal exposure to these drugs can occur on multiple levels between the mother 
and fetus41. Drugs can directly influence the fetus by crossing the placenta and uterus, 
and possibly accumulating in the amniotic fluid with altered and unknown 
pharmacokinetics and bioavailability to the fetus41. Opioids can cross the placenta in less 
than 60 minutes, resulting in maternal and fetal withdrawal to occur 6-48 hours after its 
last use42. Indirectly, drugs can influence the placenta and uterus by altering the placental 
secretory activity or uteroplacental blood flow41.  
Although opiate exposure in utero is impossible to study in humans because 
purposefully exposing the fetus to opiates would be unethical, animal studies provide 
insight into the possible pathophysiological mechanisms that may occur in humans. There 
are three major subtypes of G protein-coupled opiate receptors: mu (μ), delta (δ), and 
kappa (κ). These receptors exist in both the central and peripheral nervous systems. It is 
worth mentioning that opioid receptor expression43,44 and endogenous opioid 
concentrations in fetus/neonatal mammals differ from their adult counterparts, suggesting 
that actual exposure to opiates in utero for fetuses may differ from adult exposure45. Even 
upon birth, neonates’ meconium methadone concentrations, its metabolite concentrations, 
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and maternal methadone dose do not have a significant relationship, suggesting different 
rates of methadone elimination in neonates versus their mothers46,47. 
Animal studies show that opiates cause alterations in neurological development 
(reviewed in following references7,48). Rat models are often referenced in developmental 
studies of opioid exposure as rat responses to opioids mimic those of humans38. 
Development can be affected by the significant anatomical changes in myelination and 
myelin-forming oligodendrocytes in the brain13,14,49. Research showed a greater 
expression of myelin basic protein (MBP) and glycosylated myelin-associated 
glycoprotein when rats were exposed to equivalent buprenorphine maintenance therapy 
doses during day 7 of gestation to 21 days postnatal (estimated to be synchronous in 
development from 1st trimester to 3rd trimesters in humans41,50)13. Similar to 
buprenorphine, perinatal exposure of rats to therapeutic doses of methadone showed 
elevated levels of rat brain MBP, myelin proteolipid protein, and myelin oligodendrocyte 
glycoprotein14. These mentioned proteins have important roles in myelin formation51, 
function52, and/or maintenance53. Presence of opioid receptors in oligodendrocytes54,55, 
suggest that opioid exposure in utero may change the makeup of neurons in the brain. 
Grossly, the exposure to therapeutic doses of buprenorphine altered axonal 
growth and myelin packing distribution in the corpus callosum13,49. Specifically, corpus 
callosum sections under electron microscopy showed an increase in axons with already 
compacted myelin sheaths (>4 wraps of compacted membrane) in rats with methadone 
exposure as compared to the controls14. Immunostaining results further demonstrated that 
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both methadone and buprenorphine accelerated myelination maturation in the rat corpus 
callosum without jeopardizing the myelination maturation integrity14,49.   
Studies further demonstrate that neurological packing density and dendritic length 
are affected in different anatomical areas of the rat brain when exposed to perinatal 
morphine. Neuronal packing density decreased by 45.4% and 41.0%, while glial packing 
density is increased by 42.4% and 75.3% in the medial and lateral preoptic areas, 
respectively56. In rat brains exposed to perinatal methadone, cortical packing density of 
neurons was decreased in all II-VI areas and total dendritic length and terminal branch 
lengths were decreased in layer II/III pyramidal neurons56.  Furthermore, perinatal 
methadone exposure showed a reduction in cerebellar area and a decreased number and 
density of internal granular neurons in the cerebellum56. 
Along with the changes in oligodendrocyte maturation and anatomy, there is 
evidence that cholinergic neurons are also affected by methadone exposure in utero.  
Cholinergic neurons release acetylcholine primarily to the cerebral cortex to promote 
cortical activation during both wakefulness and rapid eye movement sleep57. Robinson et 
al. reported a delay in expression of choline acetyltransferase-immunoreactive neurons 
with reduced striatal nerve growth factor in rat striatal cholinergic neurons exposed to 
perinatal methadone58. Therefore, the disrupted cholinergic neurons of perinatal 
methadone exposure may be associated with disrupted sleep patterns in NAS58. 
Perinatal methadone exposure not only targets neuronal structure, but also 
changes the activity of neurotransmitters in the rat brain10. This was shown by alterations 
in three different pathways in methadone exposed rat brains as compared to controls by 
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measuring the following neurotransmitters and their appropriate metabolites: 1) increased 
frontal cortical dopamine for female rats, increased 3-4 Dihydroxyphenylacetic acid 
(DOPAC) for rats of both sexes, and decreased dopamine/DOPAC ratio in male rats, 2) 
decreased hippocampal norepinephrine (NE) in methadone and increased hippocampal 3-
Methoxy-4-hydroxyphenylglycol (MOPEG) and MOPEG/NE in male rats, and 3) 
increased parietal cortex serotonin when exposed to perinatal methadone only, while 
increased in metabolites 5-Hydroxyindoleacetic Acid in both striatum and frontal 
cortex10. While gender is not a significant factor in NAS in humans59, such alterations in 
neurotransmitter pathways in rats suggest possible physiological consequences of 
perinatal methadone exposure in humans. 
 
Obstetric complications 
Chronic misuse and abuse of opioids also place both the mother and fetus at 
higher risk of labor and delivery complications. High maternal and infant mortality were 
associated with pregnant women who misused opioids60,61. Underlying causes for 
maternal mortality included anesthesia complications, cardiac arrest, and physiological 
withdrawal complications61. For neonates, delivery complications include prematurity, 
premature rupture of membranes, growth restrictions, spontaneous abortion, and 
premature separation of the placenta from the uterus61–63. Although there is conflicting 
evidence available to quantify the risk of these complications, many studies suggest 
higher rates of preterm delivery (less than 37 weeks gestational age) among pregnant 
women who chronically misuse opioids61–65. Almario et al. showed that preterm labor 
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incidence among pregnant women with opioid addiction is three times higher than in the 
general population, with 9.3% giving birth before the 32 weeks of gestation65. Because 
such morbidity and mortality risks both mother and the neonate, the pregnancies of 
women who chronically misuse opioids require a close follow-up with the clinical 
providers. 
 
Neonatal abstinence and current treatments 
Newborns who were exposed to drugs of misuse in utero are at risk for 
developing physiological withdrawal upon the abrupt discontinuation of drug exposure at 
birth15. These infants are known to have, “Neonatal Abstinence Syndrome” 66–69. NAS 
symptoms generally manifest as central nervous system hyperirritability, hypertonia, 
gastrointestinal dysfunction, impaired weight gain, tremors, autonomic instability, poor 
sucking reflex, and in extreme cases, seizures4,5,62,70. The average onset of withdrawal is 
within 72 hours after birth, but symptoms can appear as late as two weeks of age62. These 
withdrawal symptoms can last as long as four weeks, depending upon the type, duration, 
and dosage of the opiate exposure4. Neonates of opioid-misusing mothers have a high 
incidence of neonatal withdrawal7, with an absolute risk of 5.9 cases of NAS per 1,000 
births to pregnant mothers who filled opioid prescriptions2.   
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Figure 1.  Neonatal Abstinence Scoring System. Sign and symptoms with 
appropriate scores assigned. Figure adapted from Nelson, Nicholas. Current Therapy in 
Neonatal-Perinatal Medicine 2nd Edition71. 
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Several tools, including Finnegan’s scoring system72 and Lipsitz’s scoring 
system73, have been proposed to assess the severity of NAS and standardize 
pharmacological interventions accordingly (reviewed extensively in Bagley et al)74,75.  
The Finnegan scoring system72 scores the NAS signs and symptoms based on their 
severity (Figure 1). In fact, the American Academy of Pediatrics (AAP) recommends the 
use of such standardized tools such as the gold-standard Finnegan scoring system for 
NAS evaluation4. Data suggests that up to 211 out of 308 methadone-exposed infants, 
with male and female neonates equally represented, who had Finnegan NAS scoring 
scores greater than or equal to eight required intervention72 during their NICU stays7,59,76. 
Consequently, BMC has NAS clinical guidelines to monitor infants with histories of 
chronic intrauterine opioid exposure for signs and symptoms of withdrawal in the 
hospital77.   
Treatment consists of a combination of non-pharmacological and pharmacological 
interventions outlined in an NAS treatment algorithm. The newborn is assessed and given 
a Finnegan score four hours after birth. Assessment of an infant continues throughout the 
NICU stay, preferably after feeds, at three to four hour intervals5. Non-pharmacological 
therapies include: minimizing sleep interruptions4,5, laser acupuncture78, music or 
massage therapy79, skin-to-skin with parents5, and frequent feeding for nutritional 
support5. Initiation of pharmacologic therapy with the first-line medications of morphine 
and methadone are indicated once a newborn starts scoring eight or above on the 
Finnegan scoring system74. Morphine is administered orally every three to four hours at 
0.3 – 1.0 mg/kg/day, titrated to effect, and then weaned every 24-28 hours after three 
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consecutive Finnegan NAS scores below eight. Methadone, on the other hand, is 
administered orally every four to 12 hours, titrated to similar ranges of 0.3 – 1.0 
mg/kg/day, but tapered based on clinical judgement due to its long-acting properties. For 
more severe withdrawal, phenobarbital, clonidine, and clonazepam have been tried as 
second-line agents4,80,81. Discharge planning at BMC for all infants with NAS includes a 
referral to early interventions by pediatric specialists for close monitoring and an 
ophthalmology referral for all infants with NAS at 4-6 months of age77. 
 
Importance of identifying ocular comorbidities in NAS 
In the eye, opioid-containing neurons have been identified in the iris-cilliary body, 
choroid membranes, cornea, lacrimal glands, and the adnexa of various species82,83. The 
opioidergic system in the eye is reviewed thoroughly in an article written by Husain and 
Potter84. Authors argue that “endogenous opioids and their receptors take part in 
accommodative power, aqueous humor dynamics, corneal wound healing, and retinal 
development84.” In rat models, the density of opioid binding sites in the retina exist in the 
same magnitude as in the brain84, which implies that the retina is similarly susceptible to 
exogenous opioids. Hence, this is another reason to characterize and recognize ocular and 
visual comorbidities in NAS. 
 Ocular and visual comorbidities such as strabismus and refractive error can even 
contribute to the overall neurodevelopment of an infant. Strabismus, defined as 
“misalignment of the eyes” by the American Association for Pediatric Ophthalmology 
and Strabismus, can disrupt the formation of normal binocular sensory neurons and visual 
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function in the visual cortex85,86. Strabismus can further be detrimental in the 
development of stereo vision as it “depends upon good vision in both eyes, excellent 
oculomotor control and cortical mechanisms for sensory fusion85.” For example, a review 
article by Read85 highlights the importance of binocular vision is important for prehesion 
along with hand grasping87–90, performing visuomotor tasks91–94, and better reading 
ability95–100. In infants and children, such deficits can foster abnormal retinal 
correspondence at a discreet level and further develop into deficits in cognitive and 
behavioral functioning101.   
Strabismus has close associations with amblyopia, “an abnormality of visual 
development characterized by decreased best-corrected visual acuity in a normal eye or in 
an eye with a structural abnormality in which visual acuity is not fully attributable to the 
structural anomaly of the eye101.” Amblyopia often occurs concurrently with strabismus; 
recognized as a known comorbidity in 50% of children with strabismus102. For children 
with developmental delay, the prevalence of amblyopia is six times greater than the full-
term infants without developmental delay103,104. The presence of such ocular conditions, 
whether amblyopia, strabismus, and/or both, can result in “suppression and anomalous 
retinal correspondence”101 at an important developmental age. Therefore, early diagnosis 
and treatment is crucial to prevent permanently reduced vision. 
Identifying such ocular pathologies in a timely manner is also important, because 
some are not only treatable, but they also have a better prognosis with early intervention. 
For example, research suggests poorer outcomes of surgery after six months among the 
children afflicted with infantile esotropia105, due to longer duration of “misaligned visual 
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input” 85. When infantile esotropia is treated before six months of age, about 74% of 
children align and achieve stereo vision105, while only 12% improve if surgically aligned 
after 24 months85. 
 
Synthesis of Existing Research 
Current clinical studies of NAS infants’ characteristics 
Imaging studies of NAS newborns show alterations in neurological anatomy 
similar to those seen in animal studies of perinatal opiate exposure. In one study, 13 
methadone exposed infants were imaged 13-44 days after birth. Results showed higher 
mean diffusivity than control infants in a small area of the left superior longitudinal 
fasciculus106. Authors argue that this may be attributed to disruptions in the myelination 
process106. In sonographic studies during the first month of life, 22 NAS infants were also 
found to have slit-like ventricles with smaller lateral ventricle and intracranial 
hemidiameter measurements11,107.   
Along with the structural changes, research suggests a genetic etiology to the 
symptomology of NAS. A prospective multi-center genetic association study of NAS 
infants based in medical centers around Massachusetts and Maine found significant 
associations between specific genetic variations and NAS outcomes108–110. Variants of 
Opioid Receptor, Mu 1 (OPRM1) and catechol-o-methyltransferase (COMT) genes were 
associated with a shorter length of stay108,109, while single nucleotide polymorphisms in 
prepronociception (PNOC) genes were associated with longer stays by 6.6 days108 among 
NAS infants with exposure to methadone or buprenorphine for greater than 30 days.  
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Insight into possible epigenetic contributions was further noted when hypermethylation 
of the OPRM1 promoter was significantly more likely to be present among the NAS 
infants requiring greater than two medications for treatment compared to those who 
required fewer110.  Given the association between OPRM1 and COMT genes and the risk 
for opioid addiction in adults109, the genetic variability displayed in infancy indicates 
possible epigenetic events occurring in utero.  
 
Impact on ocular development 
NAS has been associated with multiple ocular comorbidities15,111–113. Many reviews have 
reported cognitive and behavioral consequences of perinatal opioid exposure (reviewed in 
cited references7,48). Ocular comorbidities such as nystagmus, strabismus, amblyopia, and 
visual acuity deficit can disrupt intricate coordination of visual input and ocular growth 
further hindering proper emmetropization and visual sensory development85,114,115.   
The Lloyd and Mysercough study dedicated a section to visual maturation of NAS 
infants as it relates to ocular and visual comorbidities. The authors reported failure of 
routine vision screening in 19 out of 72 (26.4%) recruited NAS infants and a diagnosis of 
nystagmus, strabismus, or coloboma in eight more infants15. Other NAS studies have 
reported ophthalmology/orthoptist referrals in 11% to 72.5% of the study populations 
(Table 1). 
Retrospective studies of NAS further describe a prevalence of the following 
ocular comorbidities: reduced acuity, nystagmus, delayed visual maturation, strabismus, 
refractive errors, abnormal visual electrophysiology, and cerebral visual 
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impairment16,17,111–113. The five most common comorbidities and their corresponding 
prevalence percentages are listed in Table 2. Further evidence of abnormal ocular 
development in neonates exposed to opioids in utero is reported in McGlone et al’s 
descriptions of “small and immature” flash visual evoked potentials in NAS infants17. 
Many retrospective studies demonstrate higher rates of strabismus in people born 
with NAS. The overall prevalence of strabismus ranges from 1-4% among children in the 
United States between the ages of 6-72 months old116–118. Gill et al. specifically reported 
a 10-fold increase in strabismus in NAS infants when compared to the general 
population111. Retrospective studies at BMC have also reported that close to half of BMC 
study participants referred to pediatric ophthalmology was diagnosed with strabismus18. 
Many studies report similar rates of esotropia and exotropia in NAS infants18,111,119, 
however, Gupta et al. found primarily esotropia in 15 out of 16 infants exposed to either 
buprenorphine or diazepam (or both) perinatally120. 
 
Lessons from retrospective studies 
Most retrospective studies of NAS are limited by small sample size and low 
follow-up rates due to the lifestyles of many drug dependent women differ from non-drug 
dependent women17,112,113. Maternal polysubstance use, psychiatric comorbidities, and 
socioeconomic pressures may constitute additional risk factors for NAS infants41.   
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Study Patient cohort (n) % evaluated Protocol/Referral 
Spiteri et al121 223 31.9 Referral 
Hamilton et al19 20 45 Per protocol 
Nelson et al122 29 72.5 Referral 
Rosen et al123 41 100 Per protocol 
Chavez et al124 146 Unclear Per protocol 
Gill et al111 72 40/28 
(visit/phone call) 
Referral 
Dominguez et al125 10 100 Per protocol 
Traband & Lambert18 67 100 Per protocol 
Lloyd& 
Mysercough 15 
72 26.4 Per protocol 
Gupta et al120 25 40 Referral 
Kivistӧ et al119 102 11 Referral 
 
Table 1. Percentage of infants evaluated by an ophthalmologist/orthoptist.  
“Referral,” indicates a warranted referral as a result of signs and/or symptoms of ocular 
pathology, while “Per protocol” indicates a mandatory diagnostic evaluation as part of 
the study design. 
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Study Pop. 
(n) 
Strab-
ismus 
Nystagmus Reduced 
Visual 
Acuity 
Refractive 
Error 
Optic 
Nerve 
Abnorma
-lity 
 Prevalence expressed in percentages (%) 
Prevalence 
among the 
general 
population 
(6-72 months 
old) 
 1-4116–
118 
0.35126 1.2-
1.8127 
0.5- 
25.65128–
130 
0.0024131 
P
re
v
al
en
ce
 a
m
o
n
g
 t
h
e 
N
A
S
 P
o
p
u
la
ti
o
n
 
Spiteri et 
al121 
301 14 3.3 28.2 18.8 - 
Hamilton et 
al19 
20 30 70 95 30 - 
Nelson et 
al122 
29 24 - - - - 
Rosen et 
al123 
41 30* 30* - - - 
Chavez et 
al124 
146 14* 14* - - - 
Gill et al111 49 14 - - - - 
Dominguez 
et al125 
10 70 20 - - 30 
Traband & 
Lambert18 
67 49.3 17.9 - 20.9 10.4 
Lloyd& 8 50 37.5 - - - 
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Mysercough 
15 
Gupta et 
al120 
25† 64 76 12 - 8 
Kivistӧ et 
al119 
102† 10 1 - - 1 
 Average  34 30 45 23 12 
 
Table 2. Prevalence of ocular comorbidities in studies with perinatal drug exposure 
in NAS infants compared to the general population (expanded from Table 4 published 
by Spiteri-Cornish et al.121). Prevalence is expressed in percentages of the cohort 
population noted in the corresponding study. General population studies consist of 
children aged 6-72 months old. NAS population studies vary in ages included, from birth 
to 7 years old. Percentages with asterisks (*) reflect the prevalence of strabismus or 
nystagmus (not documented independently in the studies). Population numbers notated 
by the symbol (†) refer to a publication that was unclear as to whether those referred to 
an ophthalmologist had an underlying NAS diagnosis. Gupta et al. reported that at least 
12 out of 25 children were diagnosed with NAS120. Kivistӧ et al. reported that 81 out of 
102 prenatally buprenorphine-exposed infants had NAS119. 
 
 
 
  
 22 
Some studies also do not clearly differentiate the population treated for NAS from 
the population exposed to opiates in utero119,120. Other studies are further confounded by 
the inclusion of neonates of smaller gestational sizes and those who have been exposed to 
concomitant non-opiate drugs in utero, both of which can independently influence ocular 
and visual development64,120,122,123. Furthermore, due to the nature of NAS studies, which 
consist predominantly of retrospective design and case-control studies, there are many 
biases including referral bias, recall bias, and assembly bias due to small sample sizes and 
study design15,18,19,111,120. These deficiencies in the current studies highlight the need for a 
larger prospective data collection or registries, which will allow better understanding of 
the effect of opioids on a developing infant. 
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METHODS 
Study design 
The proposed study design is a prospective cohort study comparing non-drug-exposed 
infants (control group) versus NAS infants (index group) for an estimated duration of 62 
months. 
 
Study population and sampling 
This study will be conducted in the maternity unit of Boston Medical Center. The sample 
size was calculated based on alpha (α) value of 0.05 and beta (β) value of 0.85. Using the 
lowest prevalence of strabismus reported in strictly opioid exposed NAS children (14%) 
and the highest prevalence of strabismus reported in the general population (4%) (Table 
2), meaningful change expressed by delta (Δ) was determined to be 10%. Based on these 
parameters, a sample size of 129 participants is required in each study group in order to 
yield sufficient power20. 
To analyze NAS infants by the duration of drug exposure or by the concomitant 
use of drugs, the sample size was calculated by using the average prevalence of 
strabismus among NAS infants (34%), the highest prevalence of strabismus among 
general population (4%), α value of 0.05, and β value of 0.85 (Table 2). Each subgroup 
required at least 26 infants to yield sufficient power20. 
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Study variables and measures 
To understand baseline data for each infant, the following demographic data will be 
collected as listed in Table 3. 
All infants will be evaluated with a comprehensive ophthalmological exam at an 
outpatient ophthalmology clinic at 4-6 months of age. If further follow-up at the 
outpatient ophthalmology clinic is indicated, then relevant 12 month and 24 month data 
will be collected as well. Otherwise, subsequent vision screening data from the 12 
months and 24 month well-child visits with the infant’s pediatrician as recommended by 
AAP132 will be acquired. Comprehensive ophthalmological exams will identify pertinent 
findings, including visual acuity, binocular alignment, refraction, and the presence of 
nystagmus or optic nerve abnormalities as proposed in the previous retrospective study18. 
 
Recruitment 
NAS infants will be recruited by approaching mothers in their third trimester of 
pregnancy or postnatally, during the infant’s hospitalization at BMC (Boston, MA). 
Healthy, non-drug-exposed infants will also be recruited from the same maternity unit 
matched for gestational age, birth weight ± 250g, and socioeconomic status defined by 
maternal postcode at delivery.  Inclusion criteria for the NAS group are infants of 
pregnant mothers on chronic opioid therapy for 30 days or more and a singleton 
pregnancy.   
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Mother Infant 
Maternal age/race Infant Finnegan NAS scores72 and 
diagnosis 
History of drug exposure/duration/site of 
entry in utero 
NAS medication administration and 
dosage 
Mode of newborn delivery Gestational age 
Indication for Cesarean Section Number of urine toxicology (+) for drugs 
of misuse 
Anesthesia during delivery Birth weight 
Smoking status during pregnancy Gender 
Gravida and parity Ethnicity 
Hepatitis C status Head circumference at delivery 
Maternal pain medication intake during 
hospitalization and corresponding pain 
scores 
Apgar scores 
Duration of maternal time in the operating 
room/ post anesthesia care unit 
Post-natal feeding method 
Number of urine toxicology (+) for drugs 
of misuse 
Infant discharge weight 
 Maternal postal code at delivery 
 
Table 3. Demographic information to be collected from mother and infant 
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Exclusion criteria for both groups include birth prior to 36 weeks of gestation and/or 
significant neonatal illness. 
Anticipated recruitment time is approximately 36 months, considering the number 
of drug-exposed newborn admissions at BMC is estimated to be greater than 100 per 
year34, prevalence of NAS infants per intrauterine opiate exposure7, and low follow-up 
rates by mother an infant15,17.   
Difficulties in recruitment are anticipated because the encounter can be socially and 
emotionally damaging for the mothers who are already in vulnerable situations. To 
minimize such anxiety and concerns of stigmatization, only trained clinical research 
personnel will approach the mothers during the consenting process.   
 
Data collection 
Baseline characteristics listed in the study variables section will be tabulated and 
extracted by trained professional data warehouse personnel from electronic medical 
records (EMR) at BMC. Comprehensive ophthalmological exam results will be recorded 
by clinical research personnel in real time data entry capture, using a secure web-based 
application used for research studies133 (REDCap, Nashville, TN).   
Considering a staff pediatric ophthalmologist can schedule and evaluate 6 infants 
(4 new, 2 follow-up) per week, 36 months should be sufficient time for recruitment and 
evaluation. Vision screening data and follow-up at 12 and 24 month visits will also be 
extracted from the EMR by a professional personnel at BMC.  
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Data analysis by specific aims 
The dataset will be analyzed for differences between the control and the NAS infants 
groups in terms of their baseline characteristics and ocular comorbidities listed by Aims 
stated below. All statistical calculations will be performed using a commercial statistical 
software system/program available to the institution. 
Aim 1: Compare the prevalence of ocular and visual comorbidities between NAS infants 
and non-drug-exposed infants. 
The prevalence of visual and ocular comorbidities, namely of strabismus, nystagmus, 
reduced visual acuity, refractive error, and optic nerve abnormalities, will be compared 
with a series of paired t tests between NAS and non-drug-exposed infants. If any of the 
factors reach significance, chi-squared test, absolute difference in risk, and relative risk 
ratio will be calculated to assess the risk involved for the infant20.  
Aim 2: Assess the relationship between length of exposure and dose exposure of opioids 
and intrauterine concomitant substance exposure to the prevalence of ocular and visual 
comorbidities. 
NAS infants will be further divided into three subgroups by length of drug exposure in 
utero: 1) infants exposed since 1st trimester, 2) infants exposed since 2nd trimester, and 3) 
infants exposed since 3rd trimester. The prevalence of ocular and visual comorbidities in 
each group will be calculated. The length of exposure, including infants not exposed to 
opioids, and the prevalence will be compared and analyzed in a mixed-effects regression 
model. 
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Also, NAS infants will be divided into groups by number of drug classes exposed in 
utero: 1) infants exposed to opiates only, 2) infants exposed to opiates plus one other 
concomitant substance, and 3) infants exposed to opiates plus two or more concomitant 
substances. Again, the groups and prevalence of ocular and visual comorbidities will be 
compared and analyzed in a mixed-effects regression model. The primary interest of both 
comparisons is to understand their relationship to the prevalence of the comorbidities. 
Aim 3: Assess the impact of patient demographics on ocular and visual comorbidities in 
NAS infants. 
Descriptive statistics of mean and standard deviation/error, median and range will be 
calculated for the baseline characteristics of the control and NAS infants listed in Table 3. 
A series of paired t test will compare each patient demographic and calculate the 
significance to prevalence of ocular and visual comorbidities. If any of the factors reach 
significance, chi-squared test, absolute difference in risk, and relative risk ratio will be 
calculated to assess the risk involved for the infant20.  
 
Timeline and resources 
TIMELINE 
6 months  IRB submission and approval 
 Written plan for data extraction for baseline characteristics and 
follow-up 
12 – 36 
months 
 Research subject recruitment & consent 
 Data collection 
36 – 60 
months 
 EMR data extraction 
 Data collection 
 Begin data analysis 
62 months  Complete data analysis 
 Study completion 
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 Peer-review manuscript draft and submission 
 
RESOURCES 
Administrative Support 
 Clerical support 
 Clinical Research personnel for consenting, follow-up reminders, and 
real-time data entry 
 EMR data extraction 
 Statistical consulting 
Logistical Supplies 
 Consenting papers 
 Informational packets, mail reminders, and postage stamps 
 Phone calls 
 Statistical software 
 Clinic facility use 
Clinical Support 
 Pediatric Ophthalmologist consultation 
 Certified Orthoptist consultation 
 Ophthalmology technician consultation 
Registration Costs 
 Annual meetings and conferences for presentation 
 
 
Institutional Review Board 
An application for “Research Privacy Application Waiver of Authorization,” will be 
submitted to the Institutional Review Board (IRB) to protect maternal and infant 
anonymity and to minimize the stigma and psychosocial issues associated with using 
drugs of misuse as elaborated under the “Discussion” section. A full IRB protocol will be 
submitted for review to protect human participants, should the IRB recommend this 
procedure. 
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DISCUSSION 
Discussion 
NAS often occurs in the context of complex life challenges. Many mothers, who 
chronically misuse opioids, often lack financial support, social support, and stable 
housing62. Many of these women experience emotions of moderate-to-severe 
depression134,135, poor self-esteem62, and guilt and shame62. Although difficult to 
measure, the psychosocial conditions of mothers cannot be ignored as they contribute 
significantly to their infants’ overall wellbeing. This will be one major limitation of the 
study outcomes related to the neurodevelopment. 
Maternal opioid misuse warrants reporting to the Department of Children and 
Families (DCF)33, because infants are at a high risk for child neglect and subsequent 
mistreatment136,137 According to Massachusetts DCF, a home assessment along with 
family, medical, and legal interviews is required to make a placement decision33. About 
half of the infants are determined safe to remain at home and the other half of the infants 
assessed are placed in state custody33. For this reason, families impacted by NAS are 
sensitive to concerns about stigmatization and confidentiality breaches. Such negative 
experiences with the state authorities and the legal system may lead mothers with opioid 
dependence to expect similar issues with the health care system and resist treatment62. 
Researchers have found it difficult to maintain follow-up and have even reported follow-
up rates as low as 40%17. This creates a challenge for the 4-6 month comprehensive 
follow-up ophthalmology exam proposed in the present study, which may not provide 
sufficient participants to achieve the necessary statistical power. In order to be clinically 
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and statistically relevant, a longer recruitment period is needed to avoid the selection bias 
that may occur as a result of small sample sizes when participants are lost to follow-up. 
This study is designed to collect data only from BMC. The study design 
anticipates BMC, as the region’s largest safety net hospital seeing more than 100 
intrauterine drug-exposed infants per year34, will provide a sufficient recruitment of 
mother-infant dyads. Because the study will be performed at a single institution, the 
results may have limited generalizability. However, mother-infant demographics data 
will be critically evaluated and carefully compared with the previously published data in 
order to assess the generalizability of the results to the broader population.  
 
Summary 
With opioid misuse prevalent in epidemic proportions among the general population, 
NAS infants comprise a vulnerable population whose needs must be addressed. Many 
pregnant women misuse opioids and some are on methadone and/or buprenorphine for 
treatment. Perinatal opiate exposure is a risk factor for infants both in utero and 
postnatally, possibly even leading to opiate withdrawal requiring treatment. Risks due to 
maternal opioid exposure may have been underestimated. The full impact of perinatal 
opioid exposure and its developmental consequences for a generation of NAS infants 
remains unknown.   
There is compelling evidence from retrospective and case control studies that 
NAS infants display a high prevalence of ocular and visual comorbidities. This 
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manuscript proposes an innovative study of prospective design to identify the ocular and 
visual comorbidities in NAS infants in comparison to those in non-drug-exposed infants.  
 
Clinical and public health significance 
The results of the proposed study will build the evidence base about ocular and visual 
comorbidities in NAS infants resulting from in utero opioid exposure. This will help to 
establish future clinical surveillance programs for NAS infants and enable clinicians to 
develop accurate and timely ophthalmic interventions for selected infants. The patient 
demographic data will also identify possible risk factors for expanded surveillance of 
infants with a certain birthweight, gestational age, and socioeconomic characteristics. The 
ultimate goal for the proposed study is to provide data to support optimal and 
comprehensive care for this vulnerable population of opioid misusing mothers and their 
infants. 
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